AEGON ASSET MANAGEMENT UK Plc Sells 7,189 Shares of Insulet Co. (NASDAQ:PODD)

AEGON ASSET MANAGEMENT UK Plc lessened its holdings in shares of Insulet Co. (NASDAQ:PODD) by 5.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 128,360 shares of the medical instruments supplier’s stock after selling 7,189 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned 0.18% of Insulet worth $33,497,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Blue Trust Inc. boosted its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its position in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the fourth quarter worth approximately $57,000. Finally, Versant Capital Management Inc grew its holdings in shares of Insulet by 106.1% during the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares during the last quarter.

Insider Activity

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Trading Up 1.1 %

Insulet stock opened at $280.35 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $282.86. The firm has a market capitalization of $19.66 billion, a price-to-earnings ratio of 48.01, a P/E/G ratio of 3.50 and a beta of 1.22. The firm has a 50 day moving average of $267.25 and a 200 day moving average of $235.25.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. During the same period last year, the firm earned $0.71 EPS. As a group, research analysts predict that Insulet Co. will post 3.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on PODD. Citigroup increased their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Wells Fargo & Company upped their target price on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Finally, BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.